Evidence map›Paper›PMID 39931862›Full record

ReviewCurrent cancer drug targets2026

GCN2 in Cancer: Molecular Mechanisms to Therapeutic Potential.

Hayley Prescott, Makhdoom Sarwar, Martin Dickens, Evelyn Sattlegger

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cancer drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hayley PrescottSchool of Natural Sciences, Massey University, Auckland, New Zealand.
Makhdoom SarwarMaurice Wilkins Centre for Molecular BioDiscovery, University of Auckland, Auckland, New Zealand.
Martin DickensSchool of Health Sciences, Massey University, Auckland, New Zealand.ORCID 0000-0002-7605-3964
Evelyn SattleggerSchool of Natural Sciences, Massey University, Auckland, New Zealand.ORCID 0000-0002-3144-2755

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Virtually every mammalian cell contains the cytoplasmic protein kinase General Control Non-depressible 2 (GCN2), which allows cells to cope with stresses such as nutrient shortage. While GCN2 is not essential for normal cells, in many cancers GCN2 assumes a pivotal role, becoming indispensable for cell growth and survival. This has spurred significant interest in GCN2 as a promising target for anticancer therapies. In this review, we give an overview of the known links between GCN2 and cancer.

Indexed as

Antineoplastic AgentsIntegrated Stress ResponseNeoplasmsProtein Serine-Threonine KinasesAnimalsHumansMolecular Targeted TherapySignal TransductionAntineoplastic AgentsEIF2AK4 protein, humanProtein Serine-Threonine Kinasesanti-cancer treatmentcancerEIF2AK4GCN2integrated stress response.ISRprotein kinase

Identifiers

PMID39931862

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.